Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Jazz Pharma Plc (JAZZ)

Jazz Pharma Plc (JAZZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Jazz Pharma Plc FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD DUBLIN L2 D04 E5W7 IRL

www.jazzpharma.com Employees: 2,800 P: 011-353-1634 F: 353-163-4785

Description:

Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of neuroscience & oncology. It derives the majority of its revenues from its sleep disorder drugs' Xywav & Xyrem. Both drugs are approved for treating cataplexy & excessive daytime sleepiness in narcolepsy patients. Other drugs in the company's neuroscience portfolio include' Sunosi, Epidiolex & Sativex. Epidiolex is approved for treating seizures associated with two rare & severe forms of epilepsy' Lennox-Gastaut syndrome & Dravet syndrome. Sativex is approved in the U.K. & Canada as a treatment for symptom improvement in adult patients with moderate-to-severe spasticity due to multiple sclerosis. Jazz's oncology portfolio includes two drugs' Defitelio for the treatment hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation & Vyxeos for the treatment of adults with two types of acute myeloid leukemia. It received approval for two new drugs' Zepzelca & Rylaze'.

Key Statistics

Overview:

Market Capitalization, $K 7,434,152
Enterprise Value, $K 11,640,782
Shares Outstanding, K 60,455
Annual Sales, $ 3,834 M
Annual Net Income, $ 414,830 K
Last Quarter Sales, $ 1,055 M
Last Quarter Net Income, $ 215,060 K
EBIT, $ 1,268 M
EBITDA, $ 1,907 M
60-Month Beta 0.57
% of Insider Shareholders 4.20%
% of Institutional Shareholders 89.14%
Float, K 57,916
% Float 95.80%
Short Volume Ratio 0.70

Growth:

1-Year Return 2.71%
3-Year Return -4.07%
5-Year Return -18.53%
5-Year Revenue Growth 102.77%
5-Year Earnings Growth 28.76%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 6.61 on 11/06/24
Next Earnings Date N/A
Earnings Per Share ttm 16.91
EPS Growth vs. Prev Qtr 25.48%
EPS Growth vs. Prev Year 38.86%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

JAZZ Ratios

Ratio
Price/Earnings ttm 7.26
Price/Earnings forward 7.26
Price/Earnings to Growth 1.04
Return-on-Equity % 29.30%
Return-on-Assets % 9.72%
Profit Margin % 10.82%
Debt/Equity 1.47
Price/Sales 1.94
Price/Cash Flow 4.41
Price/Book 1.82
Book Value/Share 67.55
Interest Coverage 2.03
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar